Abstract: A novel hemostatic compound includes a hemostatic agent and a transdermal migration-enhancing agent, the agents combined in a defined ratio and in a form capable of topical application to an abrasion, puncture or incision site and capable at the site of inhibiting bleeding. In accordance with one embodiment of the invention, the hemostatic agent is a vasoconstrictor and/or a procoagulant, and the agents are combined in a liquid or semi-liquid form. A compound-gelling agent and/or an evaporative agent and/or an evaporative gel can be combined with the hemostatic and migration-enhancing agents in a defined ratio. In accordance with another embodiment of the invention, the invented hemostatic compound includes a hemostatic agent and a compound-gelling agent, the latter being more particularly an evaporative gel. Other components such as sterilizing, analgesic or antibacterial agents can be added to the various invented compounds.

Abstract: A novel hemostatic compound includes a hemostatic agent and a transdermal migration-enhancing agent, the agents combined in a defined ratio and in a form capable of topical application to an abrasion, puncture or incision site and capable at the site of inhibiting bleeding. In accordance with one embodiment of the invention, the hemostatic agent is a vasoconstrictor and/or a procoagulant, and the agents are combined in a liquid or semi-liquid form. A compound-gelling agent and/or an evaporative agent and/or an evaporative gel can be combined with the hemostatic and migration-enhancing agents in a defined ratio. In accordance with another embodiment of the invention, the invented hemostatic compound includes a hemostatic agent and a compound-gelling agent, the latter being more particularly an evaporative gel. Other components such as sterilizing, analgesic or antibacterial agents can be added to the various invented compounds.

Abstract: Methods and apparatus (20 ) process noninvasively measured electrical bio-impedence values and perform a technique that indicates whether there exists a change from a homeostatic fluid condition, preferably with respect to blood loss, in mammalian tissue. Analyses can be performed to determine a presence or a change in volume of fluid in an anatomical space of a mammal. A preferred implementation of such technique is embodied in an instrument that carries out a method that may predict an onset of a hemorrhagic shock condition.

Abstract: The invented non-invasive vital signs monitor is in a flexible, nominally flat planar form having integral gel electrodes, a sticky-back rear surface, an internal flex circuit capable of sensing, recording and playing out several minutes of the most recently acquired ECG waveform data and a front surface that includes an outplay port. The invented non-invasive body composition ‘risk’ monitor includes a measurement device for monitoring one or more variables including body fluid mass, dehydration, respiratory rate, blood pressure, bio-impedance, cardiography such as cardiac output, and body conformation parameters. The risk monitor may be provided in a lightweight carrying case into which the vital signs monitor plugs. Thus the two monitors may be independent or they may be integrated into one portable, non-invasive device that can convey important patient data to/from a remote patient medical data center via wireless telemetry for oversight, treatment and possible intervention by a physician.